RxDoctor Payments Data

Mark Capener, MD

Otolaryngology · Idaho Falls, IDNPI 1750489100

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Medtronic at 51.2% of the total. Reporting peaked in 2019 at $351 and has fallen 89.5% since, to $37 in 2025.

$1,541in general payments, 2019–2025

Across 48 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$790
  • Intersect ENT, Inc.$276
  • Stryker$110
  • AbbVie$61
  • Optinose US, Inc.$58
  • Acclarent, Inc$45
  • plus $201 from 8 others

What the payments were for

  • Food & beverage$1,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,541 in reported general payments places this provider in the 75th percentile of 40 otolaryngology providers in Idaho.

See all otolaryngology providers in Idaho

Medicare billing

Part B allowed, 2024
$44,186
Medicare patients
75
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cefdinir48$2,615
SynthroidLevothyroxine Sodium18$2,387
Azelastine Hcl72$1,649
Montelukast Sodium164$1,452
Ofloxacin58$1,183
Methylprednisolone130$638
Prednisone36$544
Fluconazole30$541
Levothyroxine Sodium52$457
Azithromycin134$376
Omeprazole31$347
Fluticasone Propionate25$268
Clindamycin Hcl19$232
Famotidine17$214
Mupirocin35$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$61$2,38718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 40 otolaryngology providers in Idaho.

Other otolaryngology in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →